Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
Public ClinicalTrials.gov record NCT00522834. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Phase 3 Trial of Elesclomol (STA-4783) in Combination With Paclitaxel Versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects With Stage IV Metastatic Melanoma (SYMMETRY)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
"Elesclomol (STA-4783), N-malonyl-bis (N'-methyl-N'-thiobenzoylhydrazide) is a new chemical entity with a novel structure. STA-4783 induces an oxidative stress response in cells. This response is characterized by increased production of gene families that protect against different cellular stresses, including excessive heat, the presence of reactive oxygen species such as oxygen radicals, or the presence of heavy metals. Subjects will participate in up to 2 weeks of screening during which time they will complete all screening procedures. Eligible subjects who have not received any prior cytotoxic chemotherapeutic agent for melanoma will be randomized in a 1:1 ratio to receive either STA-4783 213 mg/m2 in combination with paclitaxel 80 mg/m2 or paclitaxel 80 mg/m2 alone. One treatment cycle will consist of weekly treatments for 3 weeks, followed by a 1-week rest period. Cycles will be repeated every 4 weeks until disease progression. Tumor assessments will be performed every 8 weeks from the date of randomization or sooner if the Investigator suspects progression has occurred based on clinical signs and symptoms. "
Study identification
- NCT ID
- NCT00522834
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 630 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2007 (Type not available)
- Primary completion
- Jun 2009 (Actual)
- Completion
- Jun 2009 (Actual)
- Last update posted
- Mar 4, 2014
2007 – 2009
United States locations
- U.S. sites
- 61
- U.S. states
- 29
- U.S. cities
- 53
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Winthrop P. Rockefeller Cancer Institute | Little Rock | Arkansas | 72205 | — |
| University of California San Diego Moores UCSD Cancer Center | La Jolla | California | 92093 | — |
| University of California, San Diego | La Jolla | California | 92093 | — |
| The Angeles Clinic & Research Institute | Los Angeles | California | 90025 | — |
| Jonsson Comprehensive Cancer Center Univ. of California Los Angeles | Los Angeles | California | 90095 | — |
| Pacific Medical Center Research Institute | San Francisco | California | 94115 | — |
| Redwood Regional Medical Group | Santa Rosa | California | 94503 | — |
| Anschutz Cancer Pavillion University of Colorado | Aurora | Colorado | 80010 | — |
| Hematology Oncology, P.C. | Stamford | Connecticut | 06902 | — |
| Bay Pines VA Healthcare System | Bay Pines | Florida | — | — |
| Univ. of Miami Hospital and Clinics | Miami | Florida | 33136 | — |
| MD Anderson Cancer Center | Orlando | Florida | 32806 | — |
| Piedmont Hospital | Atlanta | Georgia | 30309 | — |
| Emory University Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Rush University Hospital | Chicago | Illinois | — | — |
| Evanston Northwestern Healthcare | Evanston | Illinois | 60201 | — |
| Joliet Oncology/Hematology Associates, LTD | Joliet | Illinois | 60435 | — |
| Oncology Specialists, S.C. | Niles | Illinois | 60714 | — |
| Oncology Specialists, SC | Park Ridge | Illinois | 60068 | — |
| Goshen Center for Cancer Care | Goshen | Indiana | 46526 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Mary Bird Perkins Cancer Center | Baton Rouge | Louisiana | 70809 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute, Wayne State University | Detroit | Michigan | — | — |
| Hubert H. Humphrey Cancer Center | Robbinsdale | Minnesota | 55422 | — |
| Ellis Fischels Cancer Center | Columbia | Missouri | — | — |
| Southeast Nebraska Hematology/Oncology | Lincoln | Nebraska | 68510 | — |
| Nebraska Methodist Cancer Center | Omaha | Nebraska | — | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Atlantic Health Research - Mountainside Hospital | Montclair | New Jersey | 07042 | — |
| University of New Mexico Cancer Center | Albuquerque | New Mexico | 87131-0001 | — |
| Monter Cancer Center North Shore Hospital | Lake Success | New York | — | — |
| Weill Medical College of Cornell University - Division of Hematology and Medical Oncology | New York | New York | 10021 | — |
| NYU Clinical Cancer Center | New York | New York | — | — |
| Stony Brook University Medical Center- Cancer Center | Stony Brook | New York | 11794-9446 | — |
| UNC School of Medicine - Division of Hematology/Oncology | Chapel Hill | North Carolina | 27599 | — |
| Carolina Hematology & Oncology Associates | Charlotte | North Carolina | 28203 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Leo W. Jenkins Cancer Center | Greenville | North Carolina | 27834 | — |
| Brody School of Medicine at East Carolina State University | Greenville | North Carolina | 27858 | — |
| Derrick L. Davis Regional Cancer Center | Winston-Salem | North Carolina | 27103 | — |
| The Christ Hospital | Cincinnati | Ohio | 45219 | — |
| The Ohio State University. | Columbus | Ohio | 43210 | — |
| Mark H. Zangmeister Cancer Center | Columbus | Ohio | 43219 | — |
| Providence Cancer Center Clinical Trials | Portland | Oregon | 97213 | — |
| St. Luke's Cancer Center | Bethlehem | Pennsylvania | 18015 | — |
| Abramson Cancer Center at University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Cancer Pavilion | Pittsburgh | Pennsylvania | 15323 | — |
| Cancer Center of the Carolinas | Greenville | South Carolina | — | — |
| Vanderbilt Medical Center | Nashville | Tennessee | 27232-6868 | — |
| Texas Oncology, PA | Dallas | Texas | 75246 | — |
| San Antonio Cancer Institute | San Antonio | Texas | 78229 | — |
| Virginia Oncology Associates | Chesapeake | Virginia | 23320 | — |
| Virginia Oncology Associates | Newport News | Virginia | 23606 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23230 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109-1023 | — |
| Marshfield Clinic | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00522834, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 4, 2014 · Synced Sep 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00522834 live on ClinicalTrials.gov.